Purpose Chemotherapy with platinum compounds and gemcitabine is frequently used in first-line treatment of advanced non-small cell lung cancer (NSCLC) patients in which tyrosine kinase inhibitors (EGFR or ALK) cannot be administered. Unfortunately, less than half of the patients achieve the benefit from chemotherapy. Gemcitabine is an analog of deoxycytidine (pyrimidine antimetabolite) with antitumor activity. The excess of deoxycytidine synthesized by RRM1 enzyme activity may be a cause of competitive displacement of gemcitabine, which reduces the efficacy of this cytostatic. The aim of this study was to determine the association between single nucleotide polymorphisms (SNPs) of the RRM1 promoter (-37C[A, -524C[T) and the effectiveness of first-line chemotherapy based on platinum compounds and gemcitabine in NSCLC patients. Patients and methods SNPs were determined by SNaPshot PCR Ò in DNA isolated from peripheral blood of 91 NSCLC patients. Results The median progression-free survival (PFS) was significantly longer in carriers of AA (-37C[A) as well as CC (-524C[T) genotype of RRM1 compared to patients with other genotypes (10.5 vs 3.5 months, p = 0.0437; HR = 2.17, 95 % CI 1.02-4.62 and 10.5 vs 3.5 months, p = 0.0343; HR = 2.12, 95 % CI 1.06-4.27). In addition, the CC genotype carriers (-37C[A) showed a significant increase in the risk of shortening overall survival (OS) in comparison to patients with AA or AC genotypes (9.5 vs 18 months, p = 0.0193; HR = 2.13, 95 % CI 1.13-4.03). Conclusions Presence of rare AA (-37C[A) and CC (-524C[T) genotypes of the RRM1 may be favorable predictive factors for chemotherapy with platinum compounds and gemcitabine in NSCLC patients.
Introduction
Non-small cell lung cancer (NSCLC, representing approx. 85 % of lung cancer cases) is still the most common cause of death (1.6 million in 2012) due to malignancies in developed countries [1] . Despite the dynamic development of medicine, the chemotherapy based on platinum compounds (cis-or carboplatin) and third generation drugs (e.g. gemcitabine) still remains standard regimen of the first-line treatment of advanced NSCLC. After administration of standard first-line chemotherapy, the objective response rates (ORR) varies between 20 and 30 %. Chemotherapy provides slight prolongation of patients' survival time (1.5 months compared to the best supportive care, BSC); however, its use is associated with occurrence of relevant toxicity. Median overall survival (OS) of patients treated by systemic therapy range from 6 to 12 months [2] . Identification of driver mutations or other gene alterations (e.g. activating mutations in the EGFR and ALK rearrangements), which are potential molecular targets, seems to be an important advancement in optimization and individualization of NSCLC therapy. These drugs significantly improved treatment outcomes (over 60 % ORR, progression free survival (PFS) prolonged to 10 months) with acceptable toxicity [3] [4] [5] [6] . Only 10-30 % (EGFR mutations) or 3-7 % (ALK rearrangements) Caucasian patients with advanced non-squamous NSCLC have molecular alterations and should be treated by target therapy. The lack of identified molecular targets for squamous cell carcinoma treatment is the reason why majority of patients still receive standard chemotherapy [7] [8] [9] . On the other hand, genetic predisposition (e.g. gene polymorphisms or mRNA expression) may be used to selection for potentially the most effective treatment regimens, which can prolong the life of patients and improve its quality [10] [11] [12] . Among the molecular changes, potentially the highest impact on the efficacy of chemotherapy have alterations of genes, which coding proteins involved in drug metabolism. Gemcitabine is frequently used in the treatment of NSCLC, ovarian and pancreatic cancer. Its mechanism of action is based on the incorporation to nucleic acids, which consequently induce apoptosis. The excess of deoxycytidine, biosynthesized with the participation of RRM1 causes competitive displacement of gemcitabine, reducing the efficacy of this chemotherapeutic agent [13, 14] . Some researchers have demonstrated that in patients with NSCLC the expression or SNPs of RRM1 may play prognostic and predictive role (e.g. for gemcitabine). The influence of single nucleotide polymorphisms (SNPs) on survival and the response to treatment with platinum compounds and gemcitabine in patients with advanced NSCLC are still not fully understood. Among the already known RRM1 SNPs, -37C[A (rs12806698) and -524C[T (rs11030918) seem to have the greatest importance as potential predictors of treatment regimens based on gemcitabine in NSCLC patients [15] [16] [17] .
The aim of this study was to determine the association between SNPs of RRM1 promoter (-37C[A, -524C[T) and the effectiveness of chemotherapy based on platinum compounds and gemcitabine in patients with inoperable or advanced NSCLC.
Materials and methods
The study was performed on 91 Caucasian patients with inoperable, locally advanced or metastatic NSCLC (IIIB and IV), treated from 2010 to 2013 at the Department of Pneumonology, Oncology and Allergology, Medical University of Lublin. NSCLC diagnosis was based on histopathological or cytological examination. In the firstline treatment all patients received standard chemotherapy, The isolation of DNA from peripheral blood leukocytes was performed using DNA Blood Mini Kit (Qiagen, Canada). Quality and quantity of extracted DNA were measured using a spectrophotometer BioPhotometer plus in cuvette equipped with UV/VIS filters (Eppendorf, Germany). Analysis of SNPs was conducted using the minisequencing technique (SNaPshot Ò PCR). For the reaction, a set of ABI PRISM SNaPshot Ò Multiplex (Life Technologies, USA) was used. An example of the results of genotyping is shown in Fig. 1 .
Statistical analysis
Statistical analysis was done using Statistica 10 (Statsoft, USA) and MedCalc 10 (MedCalc Software, Belgium). The results of p \ 0.05 were considered to be statistically significant. Using the Chi-Square (v 2 ) balance of the Hardy-Weinberg (HW) equilibrium, associations between a series factors with the distribution of RRM1 polymorphisms were calculated. The Kaplan-Meier method was used to draw a comparison curve evaluating the survival probability (PFS and OS). Cox regression model with a stepwise selection with minimum AIC factor (Akaike Information Criterion) was used to determine the influence of clinical and genetic factors on survival. The median survival in the groups was compared by the use of the U-Mann-Whitney test. of patients. Due to the fact that studied SNPs are located in the same gene (on chromosome 11) using the online tool SNAP (Broad Institute, USA) and data from the International HapMap project assesses coupling allele linkage disequilibrium (LD), LD was calculated based on data from population-based genetic studies (Utah state residents whose ancestors came from the north-western regions of Europe-CEU). Analyzed pair of SNPs has not reached the correlation coefficient R 2 [ 0.8 so, we concluded that they do not create haplotypes and are not subject to the common inheritance.
Results
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Response to chemotherapy
There were no cases of complete remission (CR) as a result of first-line chemotherapy with platinum compounds and gemcitabine. Control of the disease was observed in 54.9 % of patients, of which partial remission (PR) and stable disease (SD) occurred, respectively, in 17. 
Progression-free survival
The median PFS of whole group of patients was 4 months. In patients who were diagnosed with adenocarcinoma or non-squamous cell carcinoma compared to squamous cell carcinoma patients a significantly lower risk of shortening PFS was noticed (respectively, 6 vs 3 months, p = 0.0456, HR = 0.61, 95 % CI 0.37-0.99 and 4.5 vs 2 months, p = 0.0140, HR = 0.34, 95 % CI 0.14-0.80). In patients with IIIB stage of NSCLC and patients without anemia compared to other patients, the risk of shortening of PFS was significantly lower (respectively, 7 vs 3, p = 0.0094, HR = 0.52, 95 % CI 0.32-0.85; 6.5 vs 3 months,
Carriers of the C allele of the RRM1 (-37C[A) showed a significant increase in the risk of PFS shortening in comparison to patients with the AA genotype (3.5 vs 10.5 months, p = 0.0437; HR = 2.17, 95 % CI 1.02-4.62, Fig. 2) . Similarly, the presence of the T allele of RRM1 (-524C[T) was associated with a significant risk of shortening of PFS when confronted with the CC genotype carriers (3.5 vs 10.5 months, p = 0.0437; HR = 2.12, 95 % CI 1.06-4.27, Fig. 3) .
In a Cox multivariate logistic regression analysis, poor (PS = 1) performance status (p = 0.0117, HR = 2.75, 95 % CI 1.26-6.02) and anemia prior to treatment (p = 0.0128, HR = 2.67, 95 % CI 1.24-5.74) were Fig. 2 The probability of progression-free survival change depending on RRM1 genotype (-37C[A) Fig. 3 The probability of progression-free survival change depending on RRM1 genotype (-524C independently responsible for shortening of PFS in patients treated with chemotherapy using platinum compounds and gemcitabine (overall fit of the model: p = 0.0271, v 2 = 24.466) ( Table 3) .
Overall survival
The median OS in the study population was 12 months. The median OS was significantly longer in patients without weight loss prior to chemotherapy compared to other patients (respectively, 18 vs 7. 
Discussion
Despite progress in medicine, that has been made in recent years, there are still lack of predictive factors, which would allow qualify NSCLC patients to appropriate chemotherapy regimen. The current criteria of patients' selection to cytostatic-based therapy are primarily performance status, treatment toxicity and clinician's experience; however, it seems to be insufficient. In addition, most of the currently available chemotherapy regimens, regardless of the line of treatment, are characterized by significant differences in the effectiveness in various patients. This is another evidence that key to prediction of occurrence of resistance to cytostatics may be stored in genetic information [10-12, 18, 19] . Reliable evaluation of mRNA or protein expression requires access to the tumor tissue Tumor tissue in an advanced stages of NSCLC is difficult or, sometimes, impossible to obtain. Changes in the structure, function, stability, folding or expression of proteins may be caused by occurrence of specific SNPs in encoding or non-coding sequences (especially located in promoter region) of genes. Moreover, the analysis of SNPs may be carried out in materials that are easy to obtain (e.g. DNA from peripheral blood leukocytes) and thus easier introduced into routine clinical practice. Consequently, many studies (unfortunately mainly retrospective) assessed the effect of the individual polymorphic variants of different genes on the effectiveness of various treatment regimens.
There is lack of meta-analysis evaluating the impact of any RRM1 SNPs on response to treatment, PFS or OS in Fig. 4 The probability of overall survival change depending on RRM1 genotype (-37C[A) [23] [24] [25] .
The only evidence for association of -37A[C polymorphism and response to gemcitabine-based chemotherapy was reported in our previous study. We indicated that AC genotype was significantly related with less frequent response to chemotherapy (v 2 = 5.47, p = 0.0193). It was probably caused by the influence of A allele (importance of AA genotype was impossible to assess due to small study group). In addition, this study showed a significant association between the presence of genotype AA or AC and early progression of the disease (v 2 = 3.61; p = 0.0573) [22] .
In the available literature six studies describe the relationship between SNPs of RRM1 and the duration of the PFS (Dong et Authors demonstrated significant differences in the PFS depending on -37C[A SNP (23.3, 30.7, 24.7 weeks for Asian patients with CC, CA, AA genotype, respectively, p = 0.043) [17] . Among the studies concerning Caucasian patients, only in our previous publication the presence of a significant effect of CC genotype (-37C[A) on reduction of the risk of shortening both PFS (6 months for patients with CC genotype vs 2 months for others patients, HR = 0.51, 95 % CI 0.29-0.89, p = 0.0087) and OS (16.5 months for patients with CC and 8 months for patients CA or AA genotypes, HR = 0.47; 95 % CI 0.22-0.99, p = 0.0448) was demonstrated [22] . Other studies revealed no significant association between polymorphic variants of RRM1 (-37C[A and/or -524C[T) and the length of PFS and/or OS in patients with NSCLC treated with first-line chemotherapy.
Therefore, statistically significant relationship between -524C[T SNP of RRM1 and the PFS length (CC genotype was significantly associated with prolongation of PFS) in patients with advanced NSCLC who were treated first-line chemotherapy based on platinum compounds and gemcitabine was described for the first time in present study. We also verified the results of the impact of -37C[A SNP on the PFS (AA genotype was significantly associated with PFS prolongation) and OS (CC genotype was significantly associated with OS shortening), described previously in smaller populations of NSCLC [17, 22] . The limitations of our research are retrospective character of analysis and heterogeneous study group.
Unfortunately, despite growing evidence suggesting that SNPs in genes encoding proteins involved in drug metabolism and DNA repair may help to explain the inter-individual variability of response or resistance to chemotherapy, most of available studies present conflicting results.
Differences between studies may be due to: (1) race differences (Asian vs Caucasian patients), which are reflected both in the incidence of SNPs and in phenotypic disparity; (2) NSCLC has many subtypes (characterized by, e.g.: differences in driver mutations occurrence and clinical course) thus in most studies different proportion of each subtype may occur. Differences in course of treatment: in some studies; (3) part of patients received chemoradiation. In first-line regimens different platinum compound (cis-or carboplatin) may be used; (4) In subsequent lines most patients are treated with multiple drugs, including: pemetrexed, docetaxel, and an TKI, as well as may undergo surgery, which significantly affects course of disease and survival.
Accordingly, it is crucial to conduct a large randomized prospective studies taking into account the respective proportions of race, subtypes of NSCLC, as well as based on suitable standards and uniform regimens of treatment.
Conclusions
The presence of rare genotypes: AA (-37C[A) and CC (-524C[T) of RRM1 promoter are favorable predictors associated with prolongation of PFS in NSCLC patients treated with first-line chemotherapy with platinum compounds and gemcitabine. Moreover, occurrence of CC genotype (-37C[A) is unfavorable predictor of OS shortening. Evaluation of selected SNPs of RRM1 may in the future, become a useful tool in the qualification of patients with NSCLC to the appropriate chemotherapy regimen. However, our results should be previously confirmed in sufficiently large and prospective studies.
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